IRIS Accounts Production v25.1.3.33 09691337 Board of Directors 1.1.24 31.12.24 31.12.24 false true false false false true false iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh096913372023-12-31096913372024-12-31096913372024-01-012024-12-31096913372022-12-31096913372023-01-012023-12-31096913372023-12-3109691337ns15:EnglandWales2024-01-012024-12-3109691337ns14:PoundSterling2024-01-012024-12-3109691337ns10:Director12024-01-012024-12-3109691337ns10:PrivateLimitedCompanyLtd2024-01-012024-12-3109691337ns10:SmallEntities2024-01-012024-12-3109691337ns10:AuditExempt-NoAccountantsReport2024-01-012024-12-3109691337ns10:SmallCompaniesRegimeForDirectorsReport2024-01-012024-12-3109691337ns10:SmallCompaniesRegimeForAccounts2024-01-012024-12-3109691337ns10:FullAccounts2024-01-012024-12-310969133712024-01-012024-12-3109691337ns10:Director22024-01-012024-12-3109691337ns10:Director32024-01-012024-12-3109691337ns10:Director42024-01-012024-12-3109691337ns10:RegisteredOffice2024-01-012024-12-3109691337ns5:CurrentFinancialInstruments2024-12-3109691337ns5:CurrentFinancialInstruments2023-12-3109691337ns5:ShareCapital2024-12-3109691337ns5:ShareCapital2023-12-3109691337ns5:RetainedEarningsAccumulatedLosses2024-12-3109691337ns5:RetainedEarningsAccumulatedLosses2023-12-3109691337ns5:IntangibleAssetsOtherThanGoodwill2024-01-012024-12-3109691337ns5:DevelopmentCostsCapitalisedDevelopmentExpenditure2023-12-3109691337ns5:DevelopmentCostsCapitalisedDevelopmentExpenditure2024-01-012024-12-3109691337ns5:DevelopmentCostsCapitalisedDevelopmentExpenditure2024-12-3109691337ns5:DevelopmentCostsCapitalisedDevelopmentExpenditure2023-12-3109691337ns5:FurnitureFittings2023-12-3109691337ns5:MotorVehicles2023-12-3109691337ns5:FurnitureFittings2024-01-012024-12-3109691337ns5:MotorVehicles2024-01-012024-12-3109691337ns5:FurnitureFittings2024-12-3109691337ns5:MotorVehicles2024-12-3109691337ns5:FurnitureFittings2023-12-3109691337ns5:MotorVehicles2023-12-3109691337ns5:WithinOneYearns5:CurrentFinancialInstruments2024-12-3109691337ns5:WithinOneYearns5:CurrentFinancialInstruments2023-12-3109691337ns5:RetainedEarningsAccumulatedLosses2023-12-3109691337ns5:RetainedEarningsAccumulatedLosses2024-01-012024-12-31
REGISTERED NUMBER: 09691337 (England and Wales)















CHARLWOOD PHARMA LIMITED

Unaudited Financial Statements

for the Year Ended 31 December 2024






CHARLWOOD PHARMA LIMITED (REGISTERED NUMBER: 09691337)

Contents of the Financial Statements
for the year ended 31 December 2024










Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 3


CHARLWOOD PHARMA LIMITED

Company Information
for the year ended 31 December 2024







Directors: E M C Farrant
W Potter
A Farrant
L J Potter





Registered office: Trotwood
The Firs
Odiham
Hook
Hampshire
RG29 1PP





Registered number: 09691337 (England and Wales)





Accountants: Cooper Parry Advisory Limited
New Derwent House
69-73 Theobalds Road
London
WC1X 8TA

CHARLWOOD PHARMA LIMITED (REGISTERED NUMBER: 09691337)

Balance Sheet
31 December 2024

2024 2023
Notes £ £
Fixed assets
Intangible assets 4 92,027 123,115
Tangible assets 5 135,430 5,501
227,457 128,616

Current assets
Debtors 6 807,215 317,621
Cash in hand 475,222 570,131
1,282,437 887,752
Creditors
Amounts falling due within one year 7 (613,351 ) (391,562 )
Net current assets 669,086 496,190
Total assets less current liabilities 896,543 624,806

Provisions for liabilities (15,218 ) -
Net assets 881,325 624,806

Capital and reserves
Called up share capital 8 104 104
Retained earnings 9 881,221 624,702
Shareholders' funds 881,325 624,806

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 December 2024.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 December 2024 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 28 May 2025 and were signed on its behalf by:





W Potter - Director


CHARLWOOD PHARMA LIMITED (REGISTERED NUMBER: 09691337)

Notes to the Financial Statements
for the year ended 31 December 2024


1. Statutory information

Charlwood Pharma Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. Accounting policies

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest pound.

The financial statements have been prepared under the historical cost convention. The principle accounting policies adopted are set out below.

Turnover
Turnover represents net invoiced sales of goods and services, excluding value added tax.

Intangible assets
Intangible assets are initially measured at cost. After initial recognition, intangible assets are measured at cost
less any accumulated amortisation and any accumulated impairment losses.

Licence costs are being amortised evenly over their estimated useful life of three years.

Tangible fixed assets
Tangible fixed assets are stated at cost less depreciation. Depreciation is provided at rates calculated to write off the cost of fixed assets, less their estimated residual value, over their expected useful lives on the following bases:

Fixtures and fittings - 33% straight line
Motor vehicles - 20% straight line

Financial instruments
Trade and other debtors and creditors are classified as basic financial instruments and measured at initial recognition at transaction price. Debtors and creditors are subsequently measured at amortised cost using the effective interest rate method. A provision is established when there is objective evidence that the company will not be able to collect all amounts due.

Cash and cash equivalents are classified as basic financial instruments and comprise cash in hand and at bank and bank overdrafts which are an integral part of the company's cash management.

Financial liabilities and equity instruments issued by the company are classified in accordance with the substance of the contractual arrangements entered into and the definitions of a financial liability and an equity instrument. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

Financial assets and financial liabilities are recognised in the balance sheet when the company becomes a party to the contractual provisions of the instrument.

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.


CHARLWOOD PHARMA LIMITED (REGISTERED NUMBER: 09691337)

Notes to the Financial Statements - continued
for the year ended 31 December 2024


2. Accounting policies - continued
Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Research and development
Expenditure on research and development is written off in the year in which it is incurred.


Foreign currencies
Assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are translated into sterling at the rate of exchange ruling at the date of transaction. Exchange differences are taken into account in arriving at the operating result.

Pension costs and other post-retirement benefits
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

3. Employees and directors

The average number of employees during the year was 4 (2023 - 4 ) .

4. Intangible fixed assets
Licence
costs
£
Cost
At 1 January 2024 199,774
Additions 36,406
At 31 December 2024 236,180
Amortisation
At 1 January 2024 76,659
Amortisation for year 67,494
At 31 December 2024 144,153
Net book value
At 31 December 2024 92,027
At 31 December 2023 123,115

CHARLWOOD PHARMA LIMITED (REGISTERED NUMBER: 09691337)

Notes to the Financial Statements - continued
for the year ended 31 December 2024


5. Tangible fixed assets
Fixtures
and Motor
fittings vehicles Totals
£ £ £
Cost
At 1 January 2024 12,217 - 12,217
Additions 1,003 148,817 149,820
At 31 December 2024 13,220 148,817 162,037
Depreciation
At 1 January 2024 6,716 - 6,716
Charge for year 1,979 17,912 19,891
At 31 December 2024 8,695 17,912 26,607
Net book value
At 31 December 2024 4,525 130,905 135,430
At 31 December 2023 5,501 - 5,501

6. Debtors: amounts falling due within one year
2024 2023
£ £
Trade debtors 794,269 314,621
Other debtors 12,946 3,000
807,215 317,621

7. Creditors: amounts falling due within one year
2024 2023
£ £
Trade creditors 231,737 241,813
Taxation and social security 223,709 109,906
Other creditors 157,905 39,843
613,351 391,562

8. Called up share capital

Allotted, issued and fully paid:

Number: Class: Nominal 2024 2023
Value: £    £   
100 Ordinary £1 100 100
1 A ordinary £1 1 1
1 B ordinary £1 1 1
1 C ordinary £1 1 1
1 D ordinary £1 1 1
104 104

CHARLWOOD PHARMA LIMITED (REGISTERED NUMBER: 09691337)

Notes to the Financial Statements - continued
for the year ended 31 December 2024


9. Reserves
Retained
earnings
£

At 1 January 2024 624,702
Profit for the year 336,519
Dividends (80,000 )
At 31 December 2024 881,221